Arizona Tribune - Boulevard

NYSE - LSE

BCC	-4.57%	79	$
CMSC	-0.04%	22.82	$
BCE	-1.03%	23.26	$
NGG	-1.71%	85.98	$
CMSD	-0.61%	23.06	$
GSK	-5.97%	51.4	$
RIO	-2.07%	96.49	$
RBGPF	0.44%	63.75	$
JRI	-0.55%	12.74	$
BTI	-1.78%	57.45	$
RYCEF	-2.68%	14.9	$
BP	0.96%	46.8	$
VOD	-0.98%	15.34	$
RELX	-0.59%	35.8	$
AZN	-0.8%	185.2	$

Featured

Cambodia deports more than 600 Thais linked to cyberscams: minister

Cambodia deported more than 600 Thais allegedly involved in online scams on Thursday, the information minister said, part of a crackdown against the multibillion-dollar illicit industry that has ballooned in the country in recent years.

Afghan women footballers celebrate 'historic moment'

A FIFA rule change allowing Afghanistan's women footballers to compete in official matches is a "historic moment" and "basic human right", former captain Khalida Popal told AFP on Thursday.

Last news

Relief Therapeutics Publishes 2025 Half-Year Report

GENEVAD, SE / ACCESS Newswire / August 14, 2025 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY ) (Relief, or the Company), a biopharmaceutical company committed to delivering innovative treatment options for select specialty, unmet and rare diseases, today announced the publication of its 2025 half-year report and provided a corporate update.

CNS Pharmaceuticals to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech

- Live video webcast on Tuesday, August 19th at 2:40 PM ET

Patriot.TV Adds "The David Pollack Show" Expanding it's Weekly Lineup - Riding a Wave of Victories as Viewers Abandon Legacy Media for Streaming and Truth-Based Conservative Reporting

Patriot.TV's Ascent Coincides with a Broader Industry Shift Favoring New Media Over Legacy Networks and Conservative Over Liberal Outlets.

Lexaria's Phase 1b GLP-1 Study Achieves Important "Last Patient Last Visit" Milestone

KELOWNA, BC / ACCESS Newswire / August 14, 2025 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, is pleased to announce that its Contract Research Organization ("CRO") has completed the important study milestone known as last patent last visit ("LPLV") in Lexaria's Phase 1b glucagon-like peptide-1 ("GLP-1") study in Australia, GLP-1-H24-4 (the "Study").

Interactive Strength Inc. (Nasdaq:TRNR) Reports Second Quarter 2025 Results; Increases 2025 Pro Forma Revenue Guidance to More Than $80M

Company Reports Quarterly Revenue of $1.2 Million; Net Loss and Loss per Diluted Share of $2.2 Million and $2.13Quarterly Adjusted EBITDA Loss of $1.7 Million Reflects 40% YOY ImprovementTRNR held 29.6 Million FET tokens as of June 30, 2025 and 67.4 Million FET tokens as of August 13, 2025, with a value in excess of $50 million, representing the largest publicly traded AI-focused Digital Asset TreasuryStockholders' Equity Was $16.3 Million at Quarter End2025 Pro Forma Revenue Guidance Increased to more than $80 Million, driven by Sportstech's Stronger-Than-Expected Performance, and Fourth Quarter Profitability Guidance Reiterated

Laser Photonics (NASDAQ: LASE) Launches One-Year Integrated Media Partnership with New to The Street

Comprehensive campaign features long-form national TV interviews as sponsored programming, monthly earned media, high-frequency commercials, and iconic outdoor advertising

Wirsh Unveiled Geimori T38: The True Pro-Grade Wireless Electric Portable Coffee Grinder

Innovating on-the-go grinding with uncompromised quality and effortless precision

SafeHeal(R) Receives European Marketing Approval Under MDR for Colovac(R) Anastomosis Protection Technology

Marketing approval allows imminent commercialization of the Colovac device in key EU markets

Applied DNA Reports Third Quarter Fiscal 2025 Financial Results

STONY BROOK, NY / ACCESS Newswire / August 14, 2025 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a biotechnology company focused on providing nucleic acid production solutions for the biopharmaceutical and diagnostics industries, today reported financial results for its third quarter of fiscal 2025 ended June 30, 2025. The Company's Form 10-Q for its fiscal third quarter can be viewed on the SEC Filings page of its Investor Relations website. The Company will not host a conference call to discuss these results. Applied DNA investor relations remains available for questions at [email protected] .

Wellgistics Health Terminates Equity Line of Credit to Further Support Growth Strategy

TAMPA, FLORIDA / ACCESS Newswire / August 14, 2025 / Wellgistics Health, Inc. (NASDAQ:WGRX) ("Wellgistics Health" or the "Company"), a leader in next-generation pharmaceutical distribution, digital prescription routing, and AI-powered hub fulfillment, today announced the termination of its equity purchase agreement ("ELOC") with Hudson Global Ventures, LLC.

Labor Smart, Inc. - Letter from the CEO Q2 2025 Shareholder Update

Labor Smart, Inc. (OTCID:LTNC) - Letter from the CEO about Q2 2025 Financial Reporting

Aspire Biopharma Holdings, Inc., to Present at Sidoti Virtual Investor Conference August 20

ESTERO, FL / ACCESS Newswire / August 14, 2025 / Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP) ("Aspire" or the "Company"), developer of a multi-faceted patent-pending drug and supplement delivery technology, today announced that Kraig Higginson, Interim Chief Executive Officer of Aspire, will be presenting at the upcoming Sidoti Virtual Investor Conference on August 20 at 1:45 PM Eastern. Investors and other interested individuals may access the virtual presentation here: https://sidoti.zoom.us/webinar/register/WN_5UneWjXKTOuzgbB4wpeByg

Jaguar Health Reports Second Quarter 2025 Financials: Net Q2 2025 Revenue Up Approximately 35% Versus Net Q1 2025 Revenue

The combined net Q2 2025 revenue of approximately $3.0 million for prescription and non-prescription products, including license revenue, increased approximately 35% versus net Q1 2025 revenue of approximately $2.2 million and increased approximately 10% versus net Q2 2024 revenue of approximately $2.7 millionMytesi prescription volume increased approximately 6.5% in Q2 2025 over Q1 2025 and Mytesi prescription volume in Q2 2025 was equal to the volume in Q2 2024As announced, initial proof-of-concept results from the ongoing investigator-initiated trial in Abu Dhabi show crofelemer reduced the required total parenteral nutrition in the first participating microvillus inclusion disease (MVID) patient by up to 27% and in the first participating short bowel syndrome (SBS-IF) patient by up to 12.5%; FDA meeting resulted in planned Jaguar regulatory pathway to complete supplemental NDA strategy for crofelemer for patients with metastatic breast cancer, a population meeting orphan definition in USCompany strategy: Seek business development partnerships for license to develop and commercialize Jaguar's orphan indication products, resulting in non-dilutive funding for JaguarREMINDER: Today Jaguar to host investor webcast at 8:30 a.m. Eastern regarding Q2 2025 financials and company updates; Click here to register

ANITA & ZAHA Introduces Exclusive "Made in France" Natural Cosmetics

ANITA & ZAHA unveils a premium natural cosmetics range made in France, blending over 93% natural ingredients, luxury design, and eco-conscious values for modern, mindful beauty lovers.

Storm makes landfall in China after raking Taiwan as typhoon

Typhoon Podul weakened to a severe tropical storm when it roared ashore in southeastern China early Thursday, state media said, after carving a path across Taiwan, shutting down businesses, grounding flights and knocking out power to thousands of homes.

At least 26 migrants dead in two shipwrecks off Italy

At least 26 migrants died Wednesday when two boats sank off the coast of Italy's Lampedusa island, with around 10 others still missing, the coastguard and UN officials said.

Massive fire burns on mountain near western Canada city

Nearly 20,000 residents of a community in western Canada were on standby Wednesday as a wildfire engulfed a mountain overlooking the city of Port Alberni, the latest area threatened in the country's second-worst fire season on record.

Musk clashes with Altman after accusing App Store of favoring OpenAI

Elon Musk has accused Apple of unfairly favoring ChatGPT on its App Store and threatened legal action, triggering a fiery exchange with OpenAI CEO Sam Altman on Tuesday.

Passwords under threat as tech giants seek tougher security

Fingerprints, access keys and facial recognition are putting a new squeeze on passwords as the traditional computer security method -- but also running into public hesitancy.

Pivotree Announces Second Quarter 2025 Results

Strong gross margins and operational discipline delivers $1.7M of Adjusted EBITDA in Q2 2025, marking a third consecutive quarter of positive Adjusted EBITDA and second quarter of positive Net Income

Specificity Prepares to Launch Proprietary AI Tech Stack After Year of Strategic Transformation

TAMPA, FL / ACCESS Newswire / August 13, 2025 / Specificity, Inc. (OTCID:SPTY), a leading digital marketing agency blending proprietary ad tech with cutting-edge strategy, is finalizing development of its fully in-house, company-owned AI technology stack - a powerful asset set to redefine how the company scales, drives efficiency, and maintains its edge in the marketplace.

Mosaic Announces Agreement for Sale of Potash Mining Operations in Brazil to VL Mineração

TAMPA, FL / ACCESS Newswire / August 13, 2025 / The Mosaic Company (NYSE:MOS) announced today that it has entered into an agreement to sell Mosaic Potassio Mineração Ltda (MPM), the entity that operates the Taquari-Vassouras potash mine located in Rosário do Catete, Sergipe, Brazil, to VL Mineração Ltda. Upon the closing of the transaction, VL Mineração will pay Mosaic up to $27 million (USD) in cash including $12 million upon closing, $10 million one year after closing and $5 million over six years, and will assume responsibility for approximately $22 million in asset retirement obligations (ARO). The transaction is subject to obtaining approval by the Brazilian Administrative Council for Economic Defense (CADE) and other customary closing conditions. Mosaic expects the transaction to close by the end of 2025. Beginning in the third quarter, Mosaic will record the asset as "held for sale" with an expected book loss of $50-$70 million.

TridentCare Closes Acquisition of Shoreline Diagnostics, Solidifying Its California Presence With a Market-Leading Clinical Lab

"As an organization and harnessing our powerful, national platform, we are excited to add an in-market California lab to our national footprint," said Tomlinson. "We are excited to welcome the team from Shoreline to the existing TridentCare Lab family of over 300 phlebotomists and lab professionals in California. Existing Shoreline customers will experience uninterrupted and enhanced lab services from our expanded test menu and conversion of the lab to a 24/7 operation. Current TridentCare customers will also benefit from improved stat and routine test turnaround times."

KIFFIK Biomedical Onboards Industry Leaders Rene Veloso and Dr. Reginald Swift to Expand Business and Clinical Operations

Rene Veloso, JD, MBA, joins KIFFIK to lead investor relations and secure new funding to fuel clinical operationsRubix Life Sciences CEO Reginald Swift, Ph.D. joins as Chief Scientific Officer with responsibility to shape KIFFIK's clinical strategy

New to The Street Signs VERB Technology Company to a 1-Year Media Campaign

Filming begins today; interviews with Executive Chairman Manuel Stotz sharing the Company's New TON Digital Asset Strategy conducted this morning

NBJ Summit Unites Leaders to Navigate Market Disruption and Transformation

RANCHO PALOS VERDES, CA / ACCESS Newswire / August 13, 2025 / NBJ Summit 2025, the nutrition and dietary supplements industry's flagship invite-only event hosted by New Hope Network, wrapped up four days of high-impact conversations, collaborative leadership and future-focused insights. Top executives, thought leaders and industry experts convened to navigate the rapid shifts redefining the $70 billion dietary supplement industry. With the theme of "Nutrition Industry Transformation: Leading Through Innovation," the Summit arrived at a pivotal moment as the market evolves through convergence with healthcare, technology and shifting consumer expectations.

CV Sciences, Inc. Reports Second Quarter 2025 Financial Results

SAN DIEGO, CA / ACCESS Newswire / August 13, 2025 / CV Sciences, Inc. (OTCQB:CVSI) (the "Company", "CV Sciences", "our", "us" or "we"), a preeminent consumer wellness company specializing in hemp extracts and other proven science-backed, natural ingredients and products, today announced its financial results for the quarter ended June 30, 2025.

Desert Oasis Healthcare Supports Alzheimer's Coachella Valley and Its Upcoming "Celebration of Care" Open House

DOHC champions vital dementia support services ahead of ACV's October 29 Celebration of Care

Tenon Medical Reports Second Quarter 2025 Financial Results

~ Recently Announced Strategic Acquisition of SiVantage Portfolio Energizes Tenon's Commercial Organization and Accelerates Topline Growth ~~ FDA Clearance Unlocks New Sacro-Pelvic Market Opportunity for Catamaran® as Adjunct to Thoracolumbar Fixation with Initial Case Series Successfully Completed ~~ Operating Expenses Down 29% Year-over-Year as Company Advances Toward Integration of SiVantage Assets, Addition of Commercial Team, and full Commercial Launch of Catamaran SE ~~ Cash on Hand of Approximately $7.8 Million at Quarter End ~

Onco-Innovations Announces Closing of Private Placement

Not for distribution to United States wire services or for dissemination in the United States

Dolphin Announces Record Q2 Revenue of $14.1 Million, up 23% YoY; Deepens Investment in Women's Sports and Affiliate Marketing

CEO believes Dolphin is undervalued, purchases approximately 1% of outstanding shares since April 2025

Ensysce Biosciences Reports Second Quarter 2025 Financial Results and Latest Program Updates

Initiates Critical Milestone, Launching Phase 3 Trial of PF614 to Advance Next-Generation Opioid Therapy Toward Regulatory ApprovalReceives $5.3 Million Installment from NIDA To Support Overdose Protection ProgramAccelerates PF614-MPAR-102 Study with Full Enrollment of Part 2

Arizona Tribune - Boulevard (English)